Effect of lactoferrin on viceral fat suppression in patients with chronic liver disease; a randomized, double blind, placebo-controlled, clinical trial

Effect of lactoferrin on viceral fat suppression in patients with chronic liver disease; a randomized, double blind, placebo-controlled, clinical trial - Effect of lactoferrin on viceral fat suppression in patients with chronic liver disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004174

Enrollment

Registered

2010-10-01

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic liver disease

Interventions

Subjects will be assinged randomly to lactoferrin treated group. Subjects will be received lactoferrin 300mg/day for 8weeks. Subjects will be assinged randomly to placebo treated group. Subjects will

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.The patient of chronic liver disease 2.BMI 23kg/m2 or more

Exclusion criteria

Exclusion criteria: 1.Subjects who have already treated with anti-dyslipidemic agent 2.Sublects during pregnancy, feeding, intimation of pregnancy or intended pregnancy 3.Subjects who have already treated with interferon and ribavirin 4.Subjects who have already treated with steroids, immunosuppressive agent, and antitumor agent

Design outcomes

Primary

Measure	Time frame
The change in viceral fat (measured by helical CT scan)	—

Secondary

Measure	Time frame
1)The change in serum viral genome 2)The change in serum lipid or lipid marker levels 3)The change in serum ALT	—

Countries

Japan

Contacts

Public ContactAkito Nozaki

Yokohama City University Medical Center Gastroenterological Center

045-261-5656

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026